Regeneron Gets A Win With Eylea Approval In Diabetic Retinopathy
Executive Summary
Regeneron's workhorse blockbuster Eylea has scored another indication for diabetic retinopathy, as the company braces for new competition from Novartis later this year.
You may also be interested in...
PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis
Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar
The latest drug development news and highlights from our FDA Performance Tracker.
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO says.